NKMAX, Which Listed Its Subsidiary on Nasdaq... "Turning Eyes to the Chinese Market"

NKMAX has completed the Nasdaq listing of its U.S. subsidiary NKGen Biotech, which is responsible for pipeline development. NKGen Biotech completed a merger with Graf Acquisition Corp. IV and began trading on the Nasdaq Global Market on the 2nd.

With this listing, NKGen Biotech has acquired the capability to independently carry out pipeline development. NKMAX, which had been supporting the costs required for research and development such as clinical trial funding, has reduced its burden. It is also expected to see improvements in its financial structure. After the listing, the financial structure can be significantly improved through the recovery of previously written-off loans and valuation gains on held shares.

NKMAX appears to be accelerating its efforts to target the Chinese market next.

According to the financial investment industry on the 5th, Park Sang-woo, CEO of NKMAX, will head to China on the 11th to meet with representatives of Shoukang Group, a Chinese business partner. NKMAX has signed a business agreement with Shoukang Group, a leading medical and health services company in China, and is collaborating with them.

The two companies plan to expand their collaboration scope beyond health functional foods to include diagnostic kits and cell therapies. To strengthen their partnership, Shoukang Group is also pursuing a large-scale investment in NKMAX. In July, the two companies signed a Letter of Commitment (LOC) for a $50 million (approximately 65 billion KRW) investment.

A company official stated, “We have plans to promote the cell therapy business locally in China,” adding, “Starting with Jinan, where many top-tier hospitals are concentrated in Shandong Province, we plan to expand throughout China.”

He continued, “Shoukang Group is about to complete a large-scale nursing hospital in Jinan,” and added, “In addition to discussions on investment attraction, key topics will include commercialization of cell therapy and supply of the NK cell activity test kit ‘NKView Kit.’”

This content was produced with the assistance of AI translation services.